DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Metastatic Colorectal Cancer landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Metastatic Colorectal Cancer pipeline report also provides the inactive products analysis (dormant and terminated) along with the reasons for dormancy and discontinuation, wherever available. This report provides detailed profiles of the pipeline assets and comparative analysis of clinical and non-clinical stage products.
Metastatic Colorectal Cancer Overview
Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
Download a PDF Sample Report- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight
Metastatic Colorectal Cancer Pipeline Analysis
The report provides insights into:
- The report provides detailed insights about companies that are developing therapies in the Metastatic Colorectal Cancer
- It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer
- Metastatic Colorectal Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Colorectal Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer
The report is built using data and information traced from the researcher proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Metastatic Colorectal Cancer Emerging Drugs
- Trilaciclib: G1 Therapeutics
- Famitinib: Jiangsu Hengrui Medicine
- CMAB009: Mabpharm Limitied
- Trastuzumab Deruxtecan: Daiichi Sankyo
- SCO-101: Scandion Oncology
- BEY 1107: BeyondBio
- Etrumadenant: Arcus Biosciences
Metastatic Colorectal Cancer Pipeline Therapeutic Analysis
There are approx. 140+ key companies which are developing the therapies for Metastatic Colorectal cancer. The companies which have their Metastatic Colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, G1 Therapeutics.
Metastatic Colorectal Cancer Pipeline Phases
DelveInsight’s report covers around 140+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Metastatic Colorectal Cancer Pipeline Companies
- G1 Therapeutics
- Amgen
- Qilu Pharmaceutical
- Eisai Co Ltd
- Merck Sharp & Dohme
- Mirati Therapeutics
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
- Shanghai Henlius Biotech
- Amarin Corporation
- Mologen
- Sumitomo Dainippon Pharma Oncology
- Celltrion
- Merck Sharp & Dohme
- Jiangsu Hengrui Medicine
- Suzhou Zelgen Biopharmaceuticals
- Mabpharm Limitied
- Boehringer Ingelheim
- Chia Tai Tianqing Pharmaceutical
- Isofol Medical
- Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine
- AB Science
- Gritstone Bio, Inc
- Daiichi Sankyo
- Novartis
- Merck Sharp & Dohme
- Sunshine Guojian Pharmaceutical
- Pfizer
- Merck KGaA
- Jiangsu HengRui Medicine Co., Ltd.
- ALX Oncology
- Immunovative Therapies
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Precision Biologics
- Sanofi
- GC Pharma
- VAXIMM
- AstraZeneca
- AstraZeneca
- Yooyoung Pharmaceutical
- Med Pacto Inc.
- Exelixis
- GlaxoSmithKline
- Bristol Myers Squibb
- Merck Sharp & Dohme
- Bavarian Nordic
- Maxinovel Pharmaceuticals
- Shanghai Henlius Biotech
- Novartis
- Zucero Therapeutics
- Innovent Biologics
- Scandion Oncology
- Merck Sharp & Dohme Corp.
- AbbVie
- Beijing Biostar Technologies
- Seagen Inc
- Merck KGaA
- Teclison Ltd
- Symphogen A/S
- Sichuan Baili Pharmaceutical; SystImmune
- Karyopharm Therapeutics, and several others
Metastatic Colorectal Cancer Pipeline Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination
Metastatic Colorectal Cancer Pipeline Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Colorectal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Colorectal cancer.
- On November 18, 2021 Gilead Sciences announced that it had exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat. The two companies have also added a research collaboration deal. Arcus shares popped 15% at the news.
- In September 2021, Erasca, announced a clinical trial collaboration and supply agreement with Pfizer Inc. for the BRAF inhibitor encorafenib (BRAFTOVI®). This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
- In December 2021, Rottapharm Biotech announced a clinical collaboration with Agenus’ balstilimab (anti-PD-1) in collaboration with its lead candidate CR6086 in advanced colorectal cancer at the National Cancer Institute. Rottapharm Biotech’s clinical collaboration with Agenus offers a promising new combination therapy for patients with advanced pMMR/MSS mCRC where there is a high unmet need, and for a further range of potential applications in other immunotherapy-resistant tumors.
- On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).
- In November 2021, The US FDA granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin’s potential to benefit patients with this devastating disease.
- In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.
Metastatic Colorectal cancer Emerging Drugs Chapters
This segment of the Metastatic Colorectal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Request a PDF Sample Report- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Metastatic Colorectal cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Colorectal cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Trilaciclib: G1 Therapeutics
- Mid Stage Products (Phase II/III)
- SHR 1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Mid Stage Products (Phase II)
- Trastuzumab Deruxtecan: Daiichi Sankyo
- Early Stage Products (Phase I/II)
- NKTR-255: Nektar Therapeutics
- Early Stage Products (Phase I)
- Talimogene Laherparepvec: Amgen
- Preclinical and Discovery Stage Products
- PCS11T: Processa Pharmaceuticals
- Inactive Products
- Metastatic Colorectal cancer Key Companies
- Metastatic Colorectal cancer Key Products
- Metastatic Colorectal cancer- Unmet Needs
- Metastatic Colorectal cancer- Market Drivers and Barriers
- Metastatic Colorectal cancer- Future Perspectives and Conclusion
- Metastatic Colorectal cancer Analyst Views
- Metastatic Colorectal cancer Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/